Last week over 2,500 biomedical scientists, doctors and healthcare professionals from 58 countries visited Liverpool to attend the European Cystic Fibrosis Society (ECFS) Conference. Research conferences are an important way to advance our knowledge of CF and how to treat it, identify where the gaps in our knowledge are – and how to plug them – and most importantly, to keep research relevant to the CF community. Below are three of our highlights from the conference.
Today is Ada Lovelace Day, a day to celebrate the achievements of women in science and engineering. To mark the occasion, we caught up with Dr Paola Vergani, senior lecturer and Trust-funded researcher based at University College London. We learned about her recent research on the cystic fibrosis (CF) protein and how she’s passing on an enthusiasm in CF research to the next generation of doctors and researchers.
In a Science Media Centre briefing today, we explained to journalists why we are continuing to fund world-leading and cutting edge research to get better cystic fibrosis (CF) drugs to market, to have treatments for everyone with CF, including those not eligible or tolerant of existing drugs, and to massively reduce the impact of CF-related complications on their lives. Here, our Director of Research Dr Lucy Allen explains our plans.
As the Trust gets set to launch the second CF Insight Survey, we sat down with Head of Principal Involvement Paul Rymer, to see how your experiences are shaping our work, and how your stories are helping us turn up the volume on cystic fibrosis. Plus, we look at what’s new in this year’s survey.
The Welsh Government today announced that a deal has been agreed in principle for people with cystic fibrosis (CF) living in Wales who stand to benefit from life-saving drugs Orkambi and Symkevi, meaning that everyone in the UK will have access to the most advanced licensed therapies.
NHS Wales follows Scotland and England to provide transformational treatment to two-to-five-year-olds that can dramatically slow the progression of cystic fibrosis (CF).
People in Wales living with cystic fibrosis (CF) who have an R117H mutation will now have access to Kalydeco (ivacaftor) following meetings between the Cystic Fibrosis Trust and the All Wales Medicines Strategy Group.
